Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data showcasing the potential of its lead candidate, danegaptide, was presented at the prestigious Angiogenesis, Exudation, and Degeneration 2026 symposium on 7 February 2026.
https://breye.com/wp-content/uploads/2025/06/breye-logo_s.svg00bryteyeshttps://breye.com/wp-content/uploads/2025/06/breye-logo_s.svgbryteyes2026-02-09 08:30:272026-02-09 08:31:11Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases, today announces the successful completion of its Phase 1b clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated edema.
https://breye.com/wp-content/uploads/2025/06/breye-logo_s.svg00bryteyeshttps://breye.com/wp-content/uploads/2025/06/breye-logo_s.svgbryteyes2025-06-24 08:30:382025-06-24 08:30:45Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).
https://breye.com/wp-content/uploads/2025/06/breye-logo_s.svg00bryteyeshttps://breye.com/wp-content/uploads/2025/06/breye-logo_s.svgbryteyes2024-01-25 08:30:582024-01-25 08:31:29Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces a collaboration to develop the P2X7 receptor antagonist programme.
https://breye.com/wp-content/uploads/2025/06/breye-logo_s.svg00bryteyeshttps://breye.com/wp-content/uploads/2025/06/breye-logo_s.svgbryteyes2023-07-25 08:00:022023-07-25 08:00:02Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.
https://breye.com/wp-content/uploads/2025/06/breye-logo_s.svg00bryteyeshttps://breye.com/wp-content/uploads/2025/06/breye-logo_s.svgbryteyes2023-04-20 08:30:052023-04-20 08:33:36Breye Therapeutics Strengthens Management Team and Board
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR 4 million led by Novo Holdings and Sound Bioventures.
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data showcasing the potential of its lead candidate, danegaptide, was presented at the prestigious Angiogenesis, Exudation, and Degeneration 2026 symposium on 7 February 2026.
Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases, today announces the successful completion of its Phase 1b clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated edema.
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces a collaboration to develop the P2X7 receptor antagonist programme.
Breye Therapeutics Strengthens Management Team and Board
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.
Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases
Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR 4 million led by Novo Holdings and Sound Bioventures.